Pharmaceutical intermediates market to see growth
The global pharmaceutical intermediates market is likely to see year-on-year growth in 2019, by an estimated 3.6 percent rate.
List view / Grid view
The global pharmaceutical intermediates market is likely to see year-on-year growth in 2019, by an estimated 3.6 percent rate.
New briefing documents provide policy recommendations to help the EU tackle high medicines prices brought about by market monopolies.
Member countries of WHO have agreed to support pricing transparency for medicines, vaccines and other health products.
Global active pharmaceutical ingredients market set to surpass US$274.9 billion by 2026.
Pharmaceutical manufacturers and wholesale distributors could start losing billions of dollars because of faulty barcode scans.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a CETR grant for tuberculosis drug development.
A $100 million investment has been made to support long-term vaccine manufacturing capabilities in the US.
UK-based biotech companies raised £2.2billion from investors in 2018, an increase of 85 percent from the year before, a report has found...
NIAID has released a plan for research in the infectious disease TB in order to strengthen efforts and resolve to attack this disease...
Two years ago, Servier launched an ambitious programme of transformation to adapt to the new reality of the pharmaceutical industry. Olivier Laureau, CEO of Servier and President of the Fondation Internationale de Recherche Servier, explains the initiative and other achievements.
Niall Dickson responds to the commitment by the secretaries of state to seek a collaborative relationship with the EU in medicines regulation and supply...
NICE has approved adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer) and ustekinumab (Stelara, Janssen) for treating plaque psoriasis in children...
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.
The FDA has approved BioMarin Pharmaceutical’s bulk biologics manufacturing plant, located in Cork, Ireland for production of the formulated bulk substance.
In a healthcare world that experiences a plethora of high-cost new therapies coming to market in parallel with price increases for existing speciality drugs, pharmaceutical companies are having to move away from traditional pricing models that are largely based on demand and what the market will bear. At the same…